Lifnolix IV 500mg Infusion contains Levofloxacin, a broad-spectrum fluoroquinolone antibiotic indicated for the treatment of various bacterial infections. It is effective against a wide range of gram-positive and gram-negative pathogens, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and certain intra-abdominal infections. The intravenous formulation ensures rapid systemic availability, making it suitable for patients who are unable to take oral medications or require immediate therapeutic levels. Levofloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination, thereby leading to bacterial cell death. Lifnolix IV 500mg should be administered by slow intravenous infusion, typically over 60 minutes, with dosage adjustments based on the severity of infection, renal function, and patient-specific factors. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones, and monitoring for potential adverse effects such as tendonitis, QT interval prolongation, and central nervous system disturbances is recommended. Lifnolix IV 500mg is contraindicated in patients with known hypersensitivity to Levofloxacin or other quinolones. Proper clinical assessment and microbiological testing should guide therapy to minimize resistance development.